|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 38/1841 | (2013.01) | ||
| A61K 38/18 | (2006.01) | ||
| C07K2319/31 | (2013.01) | ||
| A61P 27/02 | (2006.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61K 38/1796 | (2013.01) |
| (11) | Number of the document | 3380121 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16869255.6 |
| Date of filing the European patent application | 2016-11-23 | |
| (97) | Date of publication of the European application | 2018-10-03 |
| (45) | Date of publication and mention of the grant of the patent | 2023-12-20 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/063557 |
| Date | 2016-11-23 |
| (87) | Number | WO 2017/091706 |
| Date | 2017-06-01 |
| (30) | Number | Date | Country code |
| 201562258934 P | 2015-11-23 | US |
| (72) |
SHERMAN, Matthew, L. , US
ATTIE, Kenneth, M. , US
|
| (73) |
Acceleron Pharma Inc. ,
128 Sidney Street, Cambridge, MA 02139,
US
|
| (54) | ACTRII ANTAGONIST FOR USE IN TREATING EYE DISORDERS |
| ACTRII ANTAGONIST FOR USE IN TREATING EYE DISORDERS |